0I3 Stock Overview A medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. More details
Rewards Risk Analysis No risks detected for 0I3 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Axonics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Axonics Historical stock prices Current Share Price US$63.50 52 Week High US$67.00 52 Week Low US$50.50 Beta 0.83 1 Month Change 4.10% 3 Month Change 7.63% 1 Year Change 22.12% 3 Year Change 17.59% 5 Year Change 166.81% Change since IPO 418.79%
Recent News & Updates
Axonics Files Form 15 Nov 26 BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders. Nov 15
Forecast breakeven date pushed back to 2025 Nov 11
Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023) Nov 09
Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic Sep 19
Second quarter 2024 earnings released: EPS: US$0.068 (vs US$0.15 loss in 2Q 2023) Aug 02 See more updates
Axonics Files Form 15 Nov 26 BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders. Nov 15
Forecast breakeven date pushed back to 2025 Nov 11
Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023) Nov 09
Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic Sep 19
Second quarter 2024 earnings released: EPS: US$0.068 (vs US$0.15 loss in 2Q 2023) Aug 02
New minor risk - Share price stability Jul 26
Forecast breakeven date moved forward to 2024 Jul 14
Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia May 18
Forecast breakeven date pushed back to 2025 May 05
First quarter 2024 earnings released: US$0.38 loss per share (vs US$0.19 loss in 1Q 2023) May 01
Forecast to breakeven in 2024 Apr 15
New minor risk - Shareholder dilution Mar 03
Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations Mar 02
Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations Mar 01
Full year 2023 earnings released: US$0.12 loss per share (vs US$1.28 loss in FY 2022) Feb 29
Insufficient new directors Feb 06
BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion. Jan 10 BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion. Jan 09
Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.
Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.34 loss in 3Q 2022) Nov 01
Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023 Oct 31
New minor risk - Share price stability Oct 13
Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 05 Axonics, Inc. Announces Chief Financial Officer Changes
Forecast breakeven date moved forward to 2024 Aug 15
Forecast breakeven date moved forward to 2024 Jul 30
Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023 Jul 29
Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 2Q 2022) Jul 28
Now 20% undervalued after recent price drop Jul 09
Now 21% undervalued after recent price drop May 18
Now 22% undervalued after recent price drop May 03
First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.50 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$1.28 loss per share (vs US$1.86 loss in FY 2021) Mar 04
Forecast to breakeven in 2025 Feb 14
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System Feb 01
Now 22% undervalued after recent price drop Jan 21 Axonics, Inc. Provides Revenue Guidance for 2023
Forecast to breakeven in 2025 Dec 31
Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023 Dec 22
Independent Director recently sold €127k worth of stock Dec 18
Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System Dec 14
Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.39 loss in 3Q 2021) Nov 02
Axonics, Inc. Updates Revenue Guidance for the Year 2022 Nov 01
Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022 Oct 11
Chief Medical Officer recently sold €751k worth of stock Sep 10
Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System Sep 09
Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.59 loss in 2Q 2021) Aug 02
Axonics, Inc. Updates Revenue Guidance for the Year of 2022 Aug 02
Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022 Jul 12
Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator Jun 01
First quarter 2022 earnings released: US$0.50 loss per share (vs US$0.57 loss in 1Q 2021) May 06
Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022 May 06
Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System Apr 20
Axonics, Inc., Annual General Meeting, May 25, 2022 Apr 16
Axonics, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
High number of new directors Mar 29
Chief Medical Officer recently sold €700k worth of stock Mar 24 Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System Mar 10
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 25
President & CFO recently sold €788k worth of stock Feb 07
President & CFO recently sold €788k worth of stock Feb 07
Axonics, Inc. Provides Earning Guidance for the Fourth Quarter and Fiscal Year of 2021 Jan 07
Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.24 loss in 3Q 2020) Nov 06
Axonics, Inc. Provides Additional Update on Inter Partes Review Proceedings Sep 24
Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.54 loss in 2Q 2020) Aug 08
Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2021 Aug 08
Axonics, Inc. Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator Jun 25
Axonics Receives FDA Approval Further Expanding MRI Labeling May 21
Axonics, Inc. has completed a Follow-on Equity Offering in the amount of $175 million. May 14
First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.43 loss in 1Q 2020) May 08
Axonics Provides Revenue Guidance for the Year 2021 May 07
Axonics Modulation Technologies, Inc. Announces Strategic Alliance with Micro Systems Technologies for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device Mar 04
Full year 2020 earnings released: US$1.49 loss per share (vs US$2.80 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX) acquired Contura Ltd. for $200 million. Feb 27
Axonics Modulation Technologies, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 23
New 90-day high: €46.60 Feb 18
Axonics Modulation Technologies, Inc. Receives FDA Approval for Third-Generation Implantable Neurostimulator Feb 17
New 90-day high: €42.40 Jan 11
Axonics Modulation Technologies, Inc. Announces Board Changes Dec 15
Axonics Modulation Technologies, Inc. Announces Publication of Fecal Incontinence Study Results for Patients Treated with R-Snm® System Nov 11
Revenue beats expectations Nov 06
Third quarter 2020 earnings released: US$0.24 loss per share Nov 06
Axonics Modulation Technologies, Inc. to Report Q3, 2020 Results on Nov 04, 2020 Oct 15
Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II Oct 06 Shareholder Returns 0I3 DE Medical Equipment DE Market 7D 2.4% -2.9% -2.6% 1Y 22.1% -8.5% 6.9%
See full shareholder returns
Return vs Market: 0I3 exceeded the German Market which returned 7.8% over the past year.
Price Volatility Is 0I3's price volatile compared to industry and market? 0I3 volatility 0I3 Average Weekly Movement 4.7% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0I3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0I3's weekly volatility (5%) has been stable over the past year.
About the Company Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence.
Show more Axonics, Inc. Fundamentals Summary How do Axonics's earnings and revenue compare to its market cap? 0I3 fundamental statistics Market cap €3.42b Earnings (TTM ) -€5.38m Revenue (TTM ) €410.83m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0I3 income statement (TTM ) Revenue US$431.90m Cost of Revenue US$101.10m Gross Profit US$330.81m Other Expenses US$336.47m Earnings -US$5.66m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/14 16:06 End of Day Share Price 2024/11/14 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Axonics, Inc. is covered by 9 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Travis Steed Barclays Travis Steed BofA Global Research Christopher Pasquale Guggenheim Securities, LLC
Show 6 more analysts 
